Peptik Ülser Hastalığı ve Medikal Tedavisi
Özet
Peptik ülser hastalığı (PÜH), mukoza katmanındaki koruyucu ve agresif faktörlerin dengesizliğinden kaynaklanan, yüzeyel lezyonlardan derin erozyonlara kadar değişebilen ciddi bir hastalıktır. Geçmişte yalnızca asit kaynaklı bir durum olarak görülürken, günümüzde hastalığın etiyolojisinde Helicobacter pylori (H. pylori) enfeksiyonunun yanı sıra sigara kullanımı, stres ve non-steroid anti-inflamatuar ilaçların (NSAİİ) rolü kabul edilmektedir. Bu doğrultuda tedavi stratejileri, basit asit baskılamadan H. pylori eradikasyonunu hedefleyen üçlü veya dörtlü kombine ilaç rejimlerine doğru evrilmiştir. Tedavide en güçlü asit inhibitörleri olan proton pompa inhibitörleri (PPİ) temel rol oynarken, antiasitler, H2 reseptör antagonistleri, sükralfat ve bizmut bileşikleri gibi ajanlardan da yararlanılmaktadır. H. pylori'nin başarılı şekilde ortadan kaldırılması ülserin iyileşmesini hızlandırır, nüksleri ve kanama gibi komplikasyonları dramatik şekilde azaltır. Diğer ana etiyolojik faktör olan NSAİİ kaynaklı ülserasyonlarda ise risk yönetimi amacıyla PPİ'ler veya misoprostol ile eş zamanlı gastrik koruma sağlanması, yaş ve kardiyovasküler risk durumuna göre tedavi protokollerinin optimize edilmesi hayati önem taşır. Refrakter vakalarda malignite, ZES ve ilaç uyumsuzluğu gibi faktörler titizlikle dışlanmalıdır.
Peptic ulcer disease (PUD) is a serious gastrointestinal disorder characterized by mucosal lesions ranging from superficial defects to deep erosions, resulting from an imbalance between protective and aggressive mucosal factors. Historically managed as an acid-driven condition, its etiology is now well-established to be primarily linked with Helicobacter pylori (H. pylori) infection, alongside critical factors like smoking, stress, and non-steroidal anti-inflammatory drugs (NSAIDs). Consequently, therapeutic strategies have shifted from solitary acid suppression to dynamic triple or quadruple drug regimens focused on H. pylori eradication. Proton pump inhibitors (PPIs) serve as the cornerstone of therapy due to their potent acid suppression, supplemented by antacids, H2 receptor antagonists, sucralfate, and bismuth preparations. Successful eradication of H. pylori accelerates ulcer healing and drastically lowers recurrence and hemorrhagic complications. For NSAID-induced ulcerations, primary prevention entails concurrent gastric protection utilizing PPIs or misoprostol, requiring clinical optimization based on individual patient age and cardiovascular risk profiles. In refractory cases that fail standard clinical interventions, underlying factors such as hidden NSAID use, patient non-compliance, Zollinger-Ellison Syndrome, and gastric malignancies must be systematically evaluated and ruled out.
Referanslar
Kalayci T, Iliklerden UH. Our Clinical Experiments of Peptic Ulcer Perforation with Literature Approache. Van Med J.2020; 27(3):335-339.
Kavitt RT, Lipowska AM, Anyane-Yeboa A, et al. Diagnosis and Treatment of Peptic Ulcer Disease. Am J Med. 2019;132(4):447-456.
Savarino V, Marabotto E, Zentilin P, et al. The appropriate use of proton-pump inhibitors. Minerva Med. 2018;109(5):386-399.
Bernshteyn MA, Masood U. Pantoprazole. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.; 2021.
Satoh K, Yoshino J, Akamatsu T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2015. J Gastroenterol. 2016;51(3):177-194.
Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018;11(11):1123-1134.
Schnoll-Sussman F, Niec R, Katz PO. Proton Pump Inhibitors: The Good, Bad, and Ugly. Gastrointest Endosc Clin N Am. 2020;30(2):239-251.
Albarki H, Pun A, Paddle PM. What is the truth about proton pump inhibitors? Curr Opin Otolaryngol Head Neck Surg. 2020;28(6):376-384.
Gross M, Aksoy J, Op den Winkel P. [Appropriate use of proton pump inhibitors (PPI)]. MMW Fortschr Med. 2020;162(20):58-65.
Pinto-Sanchez MI, Yuan Y, Bercik P, et al. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017;3(3):Cd011194.
Gyawali CP. Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe. Curr Gastroenterol Rep. 2017;19(9):46.
Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14(12):697-710.
El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14(4):447-460.
Ariel H, Cooke JP. Cardiovascular Risk of Proton Pump Inhibitors. Methodist Debakey Cardiovasc J. 2019;15(3):214-219.
Ward RM, Kearns GL. Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs. 2013;15(2):119-131.
Dovjak P. [Duodenal ulcers, gastric ulcers and Helicobacter pylori]. Z Gerontol Geriatr. 2017;50(2):159-169.
Shim YK, Kim N. The Effect of H(2) Receptor Antagonist in Acid Inhibition and Its Clinical Efficacy. Korean J Gastroenterol. 2017;70(1):4-12.
Chen J, Brady P. Gastroesophageal Reflux Disease: Pathophysiology, Diagnosis, and Treatment. Gastroenterol Nurs. 2019;42(1):20-28.
Shiotani A, Kamada T, Kusunoki H, et al. [Proton pump inhibitor H2 receptor antagonist]. Nihon Rinsho. 2011;69(6):1032-1038.
Lam JR, Schneider JL, Zhao W, et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. Jama. 2013;310(22):2435-2442.
Wang Y, Ge L, Ye Z, et al. Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: an updated systematic review and network meta-analysis of randomized trials. Intensive Care Med. 2020;46(11):1987-2000.
Budisak P, Abbas M. Bismuth Subsalicylate. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.; 2021.
Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374(9699):1449-1461.
Fischbach W, Malfertheiner P. Helicobacter Pylori Infection. Dtsch Arztebl Int. 2018;115(25):429-436.
Du LJ, Chen BR, Kim JJ, et al. Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis. World J Gastroenterol. 2016;22(12):3486-3495.
Gisbert JP. [Helicobacter pylori-associated diseases]. Gastroenterol Hepatol. 2015;38 Suppl 1:39-48.
Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother. 2021;22(6):729-741.
Malfertheiner P, Selgrad M, Bornschein J. Helicobacter pylori: clinical management. Curr Opin Gastroenterol. 2012;28(6):608-614.
Fakheri H, Saberi Firoozi M, Bari Z. Eradication of Helicobacter Pylori in Iran: A Review. Middle East J Dig Dis. 2018;10(1):5-17.
Shiota S, Yamaoka Y. Strategy for the treatment of Helicobacter pylori infection. Curr Pharm Des. 2014;20(28):4489-4500.
Nestegard O, Johnsen KM, Sørbye SW, et al. Clinical characterization of Helicobacter pylori infected patients 15 years after unsuccessful eradication. PLoS One. 2020;15(9):e0238944.
Doorakkers E, Lagergren J, Gajulapuri VK, et al. Helicobacter pylori eradication in the Swedish population. Scand J Gastroenterol. 2017;52(6-7):678-685.
Zhang M. High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment. World J Gastroenterol. 2015;21(48):13432-13437.
Tehlan A, Karmakar BC, Paul S, et al. Antibacterial action of acriflavine hydrochloride for eradication of the gastric pathogen Helicobacter pylori. FEMS Microbiol Lett. 2020;367(21).
Zhao Y, Li Y, Hu J, et al. The Effect of Helicobacter pylori Eradication in Patients with Gastroesophageal Reflux Disease: A Meta-Analysis of Randomized Controlled Studies. Dig Dis. 2020;38(4):261-268.
Melcarne L, García-Iglesias P, Calvet X. Management of NSAID-associated peptic ulcer disease. Expert Rev Gastroenterol Hepatol. 2016;10(6):723-733.
Kim BW. [Diagnosis and Treatment of Peptic Ulcer Disease: Present and Future Perspective]. Korean J Gastroenterol. 2016;67(6):318-320.
Shim YK, Kim N. [Nonsteroidal Anti-inflammatory Drug and Aspirin-induced Peptic Ulcer Disease]. Korean J Gastroenterol. 2016;67(6):300-312.
Ardalani H, Hadipanah A, Sahebkar A. Medicinal Plants in the Treatment of Peptic Ulcer Disease: A Review. Mini Rev Med Chem. 2020;20(8):662-702.
